Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wils, J.
Right arrow Articles by Labianca, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wils, J.
Right arrow Articles by Labianca, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:13-22, 2001
© 2001 European Society for Medical Oncology

review-article

Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives

J. Wils1, P. O'Dwyer2 and R. Labianca3

1Oncology Unit, Si Laurentius Hospital Roermond, The Netherlands
2University of Pennsylvania-PMC Philadelphia, Pennsylvania. USA
3Riuniti Hospital, Unit of Medical Oncology Bergamo. Italy

J Wils, MD Oncology Unit St Laurentius Hospital 6043 CN Roermond The Netherlands E-mail wils{at}mail.cobweb.nl

BACKGROUND: Despite early scepticism, several studies of systemic adjuvant 5-fluorouracil (5-FU)-based chemotherapy demonstrated significant benefits in high-risk colon cancer As many clinical investigations have since been conducted in this setting, a comprehensive literature review was undertaken to clarify the role of adjuvant therapy in the treatment of colorectal cancer

DESIGN: Current and future adjuvant treatment approaches in colorectal cancer were reviewed, and differences in the present-day North American and European practices were highlighted.

RESULTS AND CONCLUSIONS: 5-FU plus leucovonn for six months is generally considered the ‘standard’ adjuvant treatment in Dukes' stage C (stage III) colon cancer Large-scale international trials of other strategies are required to provide further advances in treatment outcome Following the lead of the USA Intergroup trials, a recently initiated cooperative effort, the Pan-European Trials in Adjuvant Colon Cancer (PETACC), may serve as a European model for such investigations In T3 and/or lymph-node positive rectal cancer, postoperative (chemo)radiotherapy in the USA is considered the adjuvant treatment of choice However, most European investigators have advocated for preoperative intensive short-course irradiation instead Randomized trials inthis area are ongoing. In the near future, new drugs for the treatment of colorectal cancer maylead to tailored therapies

adjuvant treatment, coloreclal cancer, PETACC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int J Qual Health CareHome page
B. Fervers, J. S. Burgers, M. C. Haugh, J. Latreille, N. Mlika-Cabanne, L. Paquet, M. Coulombe, M. Poirier, and B. Burnand
Adaptation of clinical guidelines: literature review and proposition for a framework and procedure.
Int. J. Qual. Health Care, June 1, 2006; 18(3): 167 - 176.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. J. Griffiths, M. Y. Koh, V. G. Brunton, C. Cawthorne, N. A. Reeves, M. Greaves, M. J. Tilby, D. G. Pearson, C. J. Ottley, P. Workman, et al.
Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis
J. Biol. Chem., October 29, 2004; 279(44): 46113 - 46121.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.